SCHEMBL15437877

SCHEMBL15437877

O=C1C(O)=C(c2ccccc2)C(=O)N1c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.47
NR1H2 P55055 1/20 0.47
NR1H3 Q13133 1/20 0.47
RAD51 Q06609 1/20 0.45
ALDH1A1 P00352 4/20 0.43
NPSR1 Q6W5P4 2/20 0.43
P2RX7 Q99572 1/20 0.43
MGLL Q99685 2/20 0.42
CDC25A P30304 1/20 0.41
CDC25B P30305 1/20 0.41
CDC25C P30307 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
FAAH O00519 1/20 0.41
GAA P10253 3/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
SCN2A Q99250 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15438309 0.88 MEN1 (0.54) NR1H2NR1H3RAD51ALDH1A1MGLL
SCHEMBL14777408 0.86 NR1H2 (0.53) ESR1NR1H2NR1H3RAD51ALDH1A1
SCHEMBL15437833 0.85 RAD51 (0.51) RAD51ALDH1A1MGLLMEN1KMT2A
SCHEMBL15757929 0.81 RAD51 (0.74) RAD51ALDH1A1MEN1KMT2AGAA
SCHEMBL28259595 0.80 ESR1 (0.47) ESR1NR1H3ALDH1A1NPSR1MEN1
SCHEMBL15437881 0.78 MGLL (0.47) NR1H2RAD51ALDH1A1P2RX7MGLL
SCHEMBL5683245 0.77 HSPA1A (0.47) ESR1NR1H2NR1H3RAD51ALDH1A1
SCHEMBL30286549 0.77 NR1H2 (0.50) ESR1NR1H2NR1H3RAD51ALDH1A1
SCHEMBL15437908 0.77 RAD51 (0.71) NR1H2NR1H3RAD51ALDH1A1NPSR1
SCHEMBL30595508 0.77 MGLL (0.50) ESR1NR1H2NR1H3RAD51ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 US claimed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 US claimed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 US claimed
CN-106483766-B Photosensitive polymer combination and the photocuring pattern formed by it 东友精细化工有限公司 2019-10-25 CN disclosed
CN-106483766-A Photosensitive polymer combination and the photocuring pattern being formed by it 东友精细化工有限公司 2017-03-08 CN disclosed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 US disclosed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 US disclosed
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof SOST, MYD88, MSR1 ESR1 771/4885NR1H2 1152/4885NR1H3 1422/4885
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof SOST, MYD88, MSR1 ESR1 530/4885NR1H2 747/4885NR1H3 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.